JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability
Morton, Magda F, Barrett, Terrance D, Freedman, Jamie, Li, Lina, Rizzolio, Michele C, Prendergast, Clodagh E, Wu, Xiaodong, Moreno, Veronica, Pyati, Jayashree, Figueroa, Katherine, Cagnon, Laurence, Lagaud, Guy, Ver Donck, Luc, Ghoos, Etienne, Allison, Brett, Rabinowitz, Michael H, Shankley, Nigel P
Published in The Journal of pharmacology and experimental therapeutics (01.07.2011)
Published in The Journal of pharmacology and experimental therapeutics (01.07.2011)
Get full text
Journal Article